Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. VSports app下载.

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Comparative Study
. 2008 Mar 11;98(5):956-64.
doi: 10.1038/sj.bjc.6604245. Epub 2008 Feb 12.

Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status

P Hofman  1 , C Butori, K Havet, V Hofman, E Selva, N Guevara, J Santini, E Van Obberghen-Schilling
Affiliations
Comparative Study

Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status

P Hofman (V体育平台登录) et al. Br J Cancer. .

Abstract

Cortactin is an actin-binding Src substrate involved in cell motility and invasion. In this study, we sought to examine the prognostic importance of cortactin protein expression in head and neck squamous cell carcinoma (HNSCC). To do so, cortactin and EGF receptor (EGFR) expression was retrospectively evaluated by immunohistochemistry in a tissue microarray composed of 176 HNSCCs with a mean follow-up time of 5 years. Cortactin immunoreactivity was weak to absent in normal epithelial tissue VSports手机版. Overexpression of the protein in 77 out of 176 tumours (44%) was associated with more advanced tumour-node-metastasis stage and higher histologic grade. Cortactin overexpression was associated with significantly increased local recurrence rates (49 vs 28% for high and low expressing carcinomas, respectively), decreased disease-free survival (17 vs 61%), and decreased the 5-year overall survival of (21 vs 58%), independently of the EGFR status. In multivariate analysis, cortactin expression status remained an independent prognostic factor for local recurrence, disease-free survival, and overall survival. Importantly, we identified a subset of patients with cortactin-overexpressing tumours that displayed low EGFR levels and a survival rate that equalled that of patients with tumoral overexpression of both EGFR and cortactin. These findings identify cortactin as a relevant prognostic marker and may have implications for targeted therapies in patients with HNSCC. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cortactin expression in normal oral mucosa and HNSCC. Staining of cortactin was performed as indicated in Materials and Methods. Normal epithelium (A–B) is devoid of staining, arrowheads indicate cortactin staining of blood vessels. Scale bar represents 200 μm in the tissue core shown in panel A and 100 μm in the higher magnification images shown in panels B–F. (C–D) Squamous cell carcinoma demonstrating strong membrane and cytoplasmic staining, respectively. (E) Squamous cell carcinoma exhibiting weak staining. (F) Squamous cell carcinoma displaying absence of immunohistochemical staining. Only strong staining (C–D) was scored as cortactin overexpression. Weak staining or absence of staining (E–F) was scored as negative for this study. Calibration bar represents 200 μm in images on the left.
Figure 2
Figure 2
Epidermal growth factor receptor and cortactin expression in HNSCC. Squamous cell carcinoma demonstrating both strong cortactin (A) and EGFR (B) coexpression. Squamous cell carcinoma demonstrating cortactin overexpression (C) and EGFR nonoverexpression (D). (Scale bar=200 μm).
Figure 3
Figure 3
Kaplan–Meier estimates of the 5-year local recurrence (A), disease-free survival (B), and overall survival (C), by cortactin status. Cortactin overexpressors had significantly lower disease-free and lower survival rates than nonoverexpressors. Additionally, cortactin overexpressors had higher local recurrence rates than nonoverexpressors. Kaplan–Meier estimates of the 5-year overall survival by both EGFR and cortactin status (D).
See this image and copyright information in PMC

References

    1. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034–3043 - PubMed
    1. Astsaturov I, Cohen RB, Harari P (2006a) Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther 6: 1179–1193 - PubMed
    1. Astsaturov I, Cohen RB, Harari PM (2006b) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 6: 691–710 - PubMed
    1. Brookes S, Lammie GA, Schuuring E, de Boer C, Michalides R, Dickson C, Peters G (1993) Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1. Genes Chromosomes Cancer 6: 222–231 - PubMed
    1. Chuma M, Sakamoto M, Yasuda J, Fujii G, Nakanishi K, Tsuchiya A, Ohta T, Asaka M, Hirohashi S (2004) Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol 41: 629–636 - PubMed

Publication types

MeSH terms